https://www.youtube.com/watch?v=5rgnTDZH2pk
Mascha Binder, MD, Martin-Luther-Universität Halle-Wittenberg, Halle, Germany, provides an overview of a debate held at the Immunotherapy of Cancer (ITOC) Co

https://blog.dana-farber.org/insight/2019/02/can-immunotherapy-be-combined-with-chemotherapy-to-fight-cancer/
It might seem that immunotherapy and chemotherapy make an unpromising pair. Chemotherapy, after all, is known to lower the immune system response, so combining it with an immune-stimulating agent might appear to be counterproductive. An illustration of a monoclonal antibody drug — a type of immunotherapy — attacking cancer cells.

https://www.verywellhealth.com/chemoimmunotherapy-4782366
Chemoimmunotherapy means combining chemotherapy drugs with immunotherapy drugs to treat cancer. Yet, in addition to combining two therapies to attack a cancer in different ways, this combination may sometimes work better than would be expected if the benefits of the two therapies were simply added together (synergy).

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8667101/
Chemo-immunotherapy combination therapy is currently being evaluated as a promising treatment, but it is not simply the one plus one. It is more important to clarify the mechanism behind the combination therapy and determine the synergy mode between the chemotherapy agents and pembrolizumab. To warrant a future combination of immunotherapy with

https://aacrjournals.org/cancerdiscovery/article/11/6/1353/666551/Paradigms-on-Immunotherapy-Combinations-with
Abstract. Checkpoint inhibitors are being added to standard-of-care chemotherapy in multiple clinical trials. Success has been reported in non-small and small cell lung carcinomas and urothelial, head and neck, gastric, and esophageal cancers, and promising results are already available in triple-negative breast and pancreatic malignancies. The potential mechanisms of synergy include

https://www.webmd.com/cancer/cancer-combination-care
Researchers are testing ways to combine immunotherapies. For example, they may mix two drugs, try one after the other, or add immunotherapy to traditional cancer treatments.

https://www.verywellhealth.com/chemotherapy-vs-immunotherapy-5324541
Summary. Chemotherapy and immunotherapy are both used in treating cancer. They help to kill cancer cells in different ways, and may be used together in some people. There are side effects to both treatments. It's important to discuss the potential side effects with your treatment team.

https://www.nature.com/articles/s41571-020-0413-z
The efficacy of chemotherapy in patients with cancer is now known to have an immunogenic component. Nonetheless, chemotherapy alone often fails to provide durable disease remission in most

https://www.healthline.com/health/cancer/immunotherapy-vs-chemotherapy
Immunotherapy and chemotherapy are two commonly used cancer treatments. Both types of therapy involve the use of drugs to stop the growth of cancer cells. Although they have the same goal, the way

https://my.clevelandclinic.org/health/treatments/11582-immunotherapy
Healthcare providers consider immunotherapy a first-line or initial treatment for many types of metastatic cancer, or cancer that's spread. They may combine immunotherapy with chemotherapy, targeted therapy or other cancer treatments. Providers use different types of immunotherapy to treat many kinds of cancer.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8462242/
Abstract. Although targeted therapies and immunotherapies have been effective against several malignancies, the respective monotherapies are limited by low and/or short-term responses. Specific inhibitors of oncogenic signaling pathways and tumor-associated angiogenesis can activate the anti-tumor immune responses by increasing tumor antigen

https://www.nature.com/articles/s41577-023-00973-8
Combinations of chemotherapy and immunotherapy. ... Single-agent activity of these agents has also been very low and early trials have attempted to combine the agents with PD1/PDL1-targeted immune

https://www.cancertherapyadvisor.com/features/combining-chemotherapy-with-immunotherapy-to-improve-response-rates/
A recent study of patients with advanced melanoma, for example, suggests that the combination of local chemotherapy and ipilimumab, a CTLA-4 inhibitor, may improve response rates and progression

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10252089/
Chemo-immunotherapy combinations were also approved in advanced biliary tract cancer , and in cervical cancer (Table 1). Nevertheless, chemo-immunotherapy has not been a panacea for all tumors. Unfortunately, despite this aforementioned remarkable success, clinical studies have not been followed by a deep mechanistic analysis or the

https://www.medicalnewstoday.com/articles/immunotherapy-vs-chemotherapy
Summary. Immunotherapy and chemotherapy are two common cancer treatments. Chemotherapy uses drugs to locate and destroy cancer cells. Immunotherapy helps a person's immune system better fight

https://jhoonline.biomedcentral.com/articles/10.1186/s13045-021-01164-5
However, chemo-immunotherapy combinations have not been a panacea in all solid tumors. In squamous NSCLC, even though the combination of pembrolizumab and chemotherapy improves OS, the addition of atezolizumab to chemotherapy did not (14.2 and 13.5 months, HR 0.88, 95% CI 0.73-1.05, p = 0.16) . In metastatic urothelial cancer, chemo

https://pubmed.ncbi.nlm.nih.gov/33712487/
Significance: Immunotherapy of cancer based on PD-1/PD-L1 blockade has prompted a revolution in cancer clinical management. Evidence in phase III clinical trials already supports combinations of immunotherapy with standard-of-care chemotherapy for a number of malignant diseases. This review focuses on such evidence and provides an overview of

https://www.verywellhealth.com/what-is-combination-chemotherapy-2248995
Combination chemotherapy is the use of more than one medication at a time to treat cancer. Since chemotherapy drugs affect cancer cells at different points in the cell cycle, using a combination of drugs increases the chance that all of the cancer cells will be eliminated. At the same time, however, multiple drugs may increase the risk of drug

https://www.nature.com/articles/nrc3237
The so-called targeted therapies and cancer immunotherapies are two novel treatment modalities that have recently begun to enter the oncology clinic. Targeted therapies and immunotherapy offer a

https://pubmed.ncbi.nlm.nih.gov/19944977/
This discussion is not limited to malignant brain tumors, because many of the studies have been conducted on various cancer types, thereby providing a comprehensive perspective that may encourage further studies that combine chemotherapy and immunotherapy for treating brain tumors.

https://medicalxpress.com/news/2024-06-inflammation-boost-immunotherapy-effectiveness-advanced.pdf
"Many oncologists might find it surprising to combine a JAK inhibitor with immunotherapy since the focus has typically been on creating a strong inflammatory response for effective anti-PD1 treatment.

https://www.msn.com/en-us/health/other/researchers-find-new-strategies-to-help-immunotherapy-annihilate-cancer/ar-BB1oETIr
The strategy to combine drugs to exploit the potential of immunotherapy has only just begun. "Despite the introduction of immunotherapy, we still have the limitation that some patients do not

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5818299/
Therefore, non-immunogenic regimens of chemotherapy, or immunogenic chemotherapy regimens that are given at a dose too low to inhibit tumor growth, are not ideal candidates to combine with immunotherapy. For chemo-immunotherapy to be effective, the dose of chemotherapy needs to be lower than the threshold dose that induces severe myeloablation

https://cancerblog.mayoclinic.org/2024/06/18/fighting-lymphoma-treatment-options-include-alternatives-to-chemotherapy/
By Sharon Theimer. Chemotherapy is usually the first treatment doctors try to treat lymphoma, including the two most common forms: non-Hodgkin and Hodgkin.But alternatives to chemotherapy are developing, as first-line treatments and as backup options, explains Stephen Ansell, M.D., Ph.D., hematology chair and hematologic oncologist at the Mayo Clinic Comprehensive Cancer Center.

https://www.science.org/doi/10.1126/science.adf1329
Cancer immunotherapy is a type of treatment that mobilizes a patient's immune system to kill tumor cells. It has been successful in treating certain tumors, but patients frequently have chronic inflammation and immunosuppression, which can limit treatment response. ... UMI barcodes were used to combine cell expression data with clonotype data

https://www.mdpi.com/2077-0383/13/13/3642
Background: There are currently few data about the safety and effectiveness of chemotherapy for patients with metastatic non-small-cell lung cancer (NSCLC) who have progressed from prior immunotherapy. Methods: Data from patients with consecutive stage IIIB-IV, ECOG performance status (PS) 0-2, non-small-cell lung cancer (NSCLC) treated with combination or single-agent chemotherapy

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9167882/
This review summarized the current status of clinically approved immune-checkpoint inhibitor-based combination immunotherapies. With several combination immunotherapies entering first-line treatment for major types of cancer including hepatocellular carcinoma (HCC), renal cell carcinoma, lung cancer, cervical cancer, and gastric cancer, it is critical to understand the limitations of these

https://www.medpagetoday.com/meetingcoverage/ascoexpertroundtabledlbcl/110806
So this is basically a chemotherapy delivery system or chemo on a stick. ... It really is an immunotherapy. So it's an antibody that has two arms, and one arm grabs a T cell and activates a T cell

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8858950/
The new combination of radiotherapy and immunotherapy shows promise in improving therapeutic efficacy and reducing recurrence by enhancing the ability of the immune system to recognize and eradicate tumor cells, to overcome tumor immune tolerance mechanisms. Nanomaterials, as new drug-delivery-system materials of the 21st century, can maintain

https://www.astrazeneca.com/media-centre/press-releases/2024/tagrisso-addition-chemotherapy-approved-japan-new-first-line-treatment-patients-egfr-mutated-advanced-lung-cancer.html
AstraZeneca's Tagrisso (osimertinib) with the addition of pemetrexed and platinum-based chemotherapy has been approved in Japan for the 1st-line treatment of adult patients with locally advanced or metastatic epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC) whose tumours have exon 19 deletions or exon 21 (L858R) mutations.